Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Honey paste could melt artery plaque and lower cholesterol

NCT ID NCT07314775

Disease control Sponsor: Xinjiang Uygur Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether Yangxin Dawayimixike Honey Paste can reduce carotid artery plaque and improve cholesterol in people with dyslipidemia. Over 400 participants will receive either the honey paste or a placebo for 12 months, with a one-year follow-up. The main goal is to see if the paste thickens the artery wall less and lowers the risk of heart problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Yangxin Dawayimixike Honey Paste
What this could lead to
If it works, this honey paste could help reduce carotid artery plaque and improve cholesterol levels, potentially lowering heart attack and stroke risk.
What could go wrong
This is an early-stage Phase 4 trial with no results yet. The treatment may not outperform placebo, and long-term safety is still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 422 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Meets the diagnostic criteria for Carotid Atherosclerotic Plaque (CAP); 2. Meets the diagnostic criteria for dyslipidemia; 3. Meets the TCM syndrome differentiation criteria for Qi Stagnation and Blood Stasis pattern; 4. Aged 18-75 years, both sexes eligible; 5. Vital signs stable, conscious with normal communication ability; 6. Subject voluntarily participates and signs the informed consent form. Exclusion Criteria: 1. Patients with severe cardiovascular diseases, including acute myocardial infarction, unstable angina, NYHA Class II-IV heart failure, severe arrhythmias, congenital heart disease, or severe valvular heart disease; 2. Patients with poorly controlled hypertension (systolic blood pressure ≥180 mmHg or diastolic blood pressure \>100 mmHg), severe cerebrovascular diseases, hemorrhagic or hematologic disorders, or malignant tumors; 3. Patients with hepatic dysfunction, defined as alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels exceeding twice the upper limit of normal, or renal insufficiency, defined as serum creatinine levels exceeding 1.5 times the upper limit of normal; 4. Patients with severe psychological disorders, intellectual disabilities, or language barriers; 5. Pregnant or lactating women; 6. Patients with known hypersensitivity to the investigational drug; 7. Patients concurrently participating in other clinical trials.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carotid atherosclerotic plaques are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Dyslipidemias inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carotid atherosclerotic plaques Dyslipidemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.